THIRD AMENDMENT TO RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • June 20th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations
This THIRD AMENDMENT TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (the “Third Amendment”) is effective as of June 18, 2019 (“Third Amendment Effective Date”), by and between ULTRAGENYX PHARMACEUTICAL INC., a Delaware corporation having an address at 60 Leveroni Court, Novato, CA, 94949 (“Ultragenyx”), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation having an address at 10628 Science Center Drive, Suite 250, San Diego, CA 92121 (“Arcturus”), and, solely for purposes of Section 5(b), ARCTURUS THERAPEUTICS HOLDINGS INC, a Delaware Corporation (“Arcturus Parent”), and amends that certain Research Collaboration and License Agreement between the Parties, dated October 26, 2015, as amended on October 17, 2017 and April 20, 2018 (the “License Agreement”).
REGISTRATION RIGHTS AGREEMENT by and between ARCTURUS THERAPEUTICS HOLDINGS INC. and ULTRAGENYX PHARMACEUTICAL INC. Dated as of June 18, 2019Registration Rights Agreement • June 20th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 18, 2019, is by and between Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Company”), and Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”).
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • June 20th, 2019 • Arcturus Therapeutics Ltd. • Pharmaceutical preparations • Delaware
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is made as of June 18, 2019, by and among Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Investor”), Arcturus Therapeutics Ltd., an Israeli incorporated company (“Arcturus-Israel”), and Arcturus Therapeutics Holdings Inc., a newly incorporated Delaware corporation (“Arcturus-Delaware”).
